Toronto Dominion Bank acquired a new stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,436,900 shares of the company's stock, valued at approximately $14,355,000. Toronto Dominion Bank owned 6.41% of Oaktree Acquisition Corp. III Life Sciences at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the stock. AQR Arbitrage LLC bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at about $19,743,000. Shaolin Capital Management LLC bought a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $5,478,000. Two Sigma Investments LP bought a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $4,358,000. Lighthouse Investment Partners LLC bought a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $3,039,000. Finally, TENOR CAPITAL MANAGEMENT Co. L.P. bought a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter valued at about $2,988,000.
Oaktree Acquisition Corp. III Life Sciences Stock Up 0.1%
OACC stock traded up $0.01 during mid-day trading on Friday, hitting $10.45. The stock had a trading volume of 1,220 shares, compared to its average volume of 116,979. Oaktree Acquisition Corp. III Life Sciences has a 52 week low of $9.95 and a 52 week high of $10.85. The stock's fifty day moving average is $10.29.
About Oaktree Acquisition Corp. III Life Sciences
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
Featured Articles
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
